Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Inclusion Criteria: * Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary. * Platinum resistant or refractory ovarian cancer * At least treated with one line of platinum-based chemotherapy * Female, age ≥18 years and ≤70 years, signed informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version * Patients must have a life expectancy of at least 3 months. * Patients must have adequate organ function as defined by the following criteria: * White blood cell count ≥ 3 x 10\^9/L, Absolute neutrophil count (ANC) (≥ 1.0 x 10\^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 80 x 10\^9/L * Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2.5 x ULN * Serum creatinine ≤ 1 x ULN * Symptomatic central nervous system (CNS) metastasis Exclusion Critera: * Has known allergies to any of the excipients. * Prior treatment with adriamycin or other anthracycline at cumulative doses greater than 550 mg/m2 after 6 cycles of pegylated liposomal doxorubicin * LVEF (left ventricular ejection fraction) \<50% * Had disease recurrence/progression within 6 months after the administration of doxorubicin chemotherapy * History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1. * Known significant chronic liver disease, such as cirrhosis or active hepatitis * Uncontrollable active infection